Aditxt, Inc. Files 8-K for Jan 13, 2025
Ticker: ADTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1726711
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
Aditxt filed an 8-K on 1/13/25 - check for updates.
AI Summary
Aditxt, Inc. filed an 8-K on January 13, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Aditx Therapeutics, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Mountain View, California.
Why It Matters
This filing indicates Aditxt, Inc. is providing updates and financial information to the SEC, which is crucial for investors to stay informed about the company's status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains updates on corporate events or financial information, and does not inherently signal significant risk.
Key Numbers
- 001-39336 — SEC File Number (Identifies the company's filing with the SEC.)
- 82-3204328 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aditxt, Inc. (company) — Registrant
- Aditx Therapeutics, Inc. (company) — Former company name
- January 13, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 2834 (sic_code) — Standard Industrial Classification for Pharmaceutical Preparations
- Mountain View, CA (location) — Address of principal executive offices
FAQ
What specific events are detailed in the Regulation FD Disclosure?
The provided text does not specify the content of the Regulation FD Disclosure, only that it is part of the filing.
What financial statements are included in this filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific statements are not detailed in the provided text.
What was the previous name of Aditxt, Inc. and when did the name change occur?
Aditxt, Inc. was formerly known as Aditx Therapeutics, Inc. The filing mentions name changes on November 13, 2020, and December 29, 2017, but does not specify which name change corresponds to 'Aditx Therapeutics, Inc.'.
Where are Aditxt, Inc.'s principal executive offices located?
Aditxt, Inc.'s principal executive offices are located at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043.
What is Aditxt, Inc.'s Standard Industrial Classification (SIC) code?
Aditxt, Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 839 words · 3 min read · ~3 pages · Grade level 13.1 · Accepted 2025-01-13 08:15:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ADTX The Nasdaq Stock Market LLC
Filing Documents
- ea0227474-8k_aditxt.htm (8-K) — 30KB
- ea022747401ex99-1_aditxt.htm (EX-99.1) — 10KB
- 0001213900-25-002846.txt ( ) — 216KB
- adtx-20250113.xsd (EX-101.SCH) — 3KB
- adtx-20250113_lab.xml (EX-101.LAB) — 33KB
- adtx-20250113_pre.xml (EX-101.PRE) — 22KB
- ea0227474-8k_aditxt_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure On January 13, 2025, Aditxt, Inc. (the " Company ") issued a press release announcing that its Board of Directors has authorized management to explore taking its subsidiary, Pearsanta, Inc. (" Pearsanta ") public via a proposed initial public offering in 2025. A copy of the press release is furnished to this Current Report on Form 8-K as Exhibit 99.1 The Company can provide no assurance that the proposed initial public offering of Pearsanta will occur in 2025, if ever. Management is undertaking preliminary exploratory measures regarding a potential initial public offering of Pearsanta and the Board of Directors will continue to evaluate all strategic possibilities consistent with its fiduciary duties. Any decision with respect to a potential transaction remains subject to approval by the Company's Board of Directors. In addition, consummation of the initial public offering is subject to market conditions. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing. Cautionary Language Regarding Forward-Looking This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may ca
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit No. Exhibit 99.1 Press release dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the XBRL document) -1- SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 Aditxt, Inc. By: /s/ Amro Albanna Name: Amro Albanna Title: Chief Executive Officer -2-